Takeda and Finch to Develop Microbiotic Drug for Ulcerative Colitis
By Vipul Sikka
Pharma Deals Review: Vol 2017 Issue 5 (Table of Contents)
Published: 5 May-2017
DOI: 10.3833/pdr.v2017.i5.2241 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Takeda has licensed exclusive worldwide rights to develop and commercialise Finch Therapeutics' inflammatory bowel disease (IBD) candidate, FIN-524, and any follow-on products for an upfront payment of US$10 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS